LMMYOTCServices-Educational ServicesFiscal year ends May 31

Exousia Bio, Inc.

Financials through Q3 FY2026, quarter ended Feb 28, 2026Last filing: 10-Q on Jun 16, 2026

$0.01−0.00 (-18.29%)

Close on Oct 19, 2026

Market cap: $175.47K
P/E (TTM): –
Dividend yield: –

Exousia Bio, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-05-31	FY 2024 2024-05-31	FY 2023 2023-05-31
Revenue	0.00	0.01	0
Cost of Revenue	0.01	0.01	0
Gross Profit	0.00	0.00	0
General & Administrative	0.03	0.03	0.06
Operating Expenses	0.03	0.03	0.06
Operating Income	–	–	-0.06
Other Non-Operating Income	0.09	0.00	0
Asset Impairment Charges	0.00	0	–
Pretax Income	0.05	-0.03	-0.06
Income Tax Expense	0	0	0
Net Income	0.05	-0.03	-0.06
EPS (Basic)(per share)	0.00	0.00	0.00
EPS (Diluted)(per share)	0.00	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	7.78	7.78	5.69
Shares Outstanding (Diluted, Weighted)(shares)	7.78	7.78	5.69

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Feb 28, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -187.2%

Financial strength

Current ratio: 0.00
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.01
Dividend yield: –